So, Amneal Pharmaceuticals Amneal Pharmaceuticals Inc. (AMRX) had a pretty good quarter. The generic and specialty drugmaker released its financial results on Friday, and the numbers tell a story of solid growth.

Here's the headline: fourth-quarter revenue hit $814.32 million. That's an 11% jump from the same period last year, and it managed to beat the consensus estimate of $807.89 million. On the bottom line, adjusted earnings came in at 21 cents per share, topping the Wall Street estimate of 18 cents. Adjusted EBITDA, a measure of cash profitability, reached $175 million, up 13% year-over-year.

What's driving this? The company pointed to two main things. First, there's strong uptake of its specialty products, with CREXONT getting a specific shoutout. Second, its Affordable Medicines segment—that's the generic drugs business—has been seeing a "robust cadence" of new product approvals. In other words, they're getting more generic drugs to market, which is kind of the whole game in that business.

Looking Ahead to 2026

Now, for the future. Companies love to give guidance, and Amneal's outlook for fiscal 2026 is interesting. They expect adjusted earnings to land between 93 cents and $1.03 per share. The consensus estimate was sitting at 94 cents, so the high end of their range is a bit above what analysts were expecting.

On the sales front, they're forecasting $3.05 billion to $3.15 billion. The consensus was a tad higher at $3.21 billion, so that's a slight miss on the top-line guidance. They also expect adjusted EBITDA of $720 million to $760 million and operating cash flow between $325 million and $375 million.

What the Charts Are Saying

Let's talk about the stock for a minute. From a technical analysis perspective, the picture is a bit mixed. The stock is currently trading 5.2% below its 20-day simple moving average and 6.8% below its 100-day average, which suggests some short-term weakness. Over the past 12 months, though, shares are up 16%, and they're closer to their 52-week highs than lows, which paints a generally positive longer-term trend.

The Relative Strength Index (RSI) is sitting right at 50.00. That's the definition of neutral—not overbought, not oversold. Meanwhile, the MACD indicator is at 0.10, which is below its signal line of 0.15. That's typically read as a bearish signal. So you've got neutral RSI and bearish MACD, which creates a mixed momentum picture. Traders watching this might be looking for a clearer signal to emerge.

On the chart, key resistance is seen at $15.00, with key support down at $13.00.

What the Analysts Think

The analyst consensus on Amneal is a Buy rating, with an average price target of $11.83. A notable recent move came from Barclays, which initiated coverage back on December 9, 2025, with an Overweight rating and a $15.00 price target.

As for the stock's immediate reaction, Amneal shares were up 0.76% at $14.60 in premarket trading on Friday, according to market data.